Gen-Probe Pursues Hepatitis Assay BLA To Drive Tigris Adoption
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe seeks to expand offerings for its Tigris automated nucleic acid test (NAT) platform by initiating a study of the Procleix Ultrio HIV-1, hepatitis B and C assay this month
You may also be interested in...
Gen-Probe Procleix Ultrio
Biologics license application is submitted to FDA for a blood screening assay to detect HIV-1, hepatitis C & B in donated blood, plasma, organs and tissue. The test is intended to be marketed by Chiron and run on fully automated, high-throughput Procleix Tigris and semi-automated Procleix systems (1"The Gray Sheet" Jan. 5, 2004, p. 5)...
Gen-Probe Procleix Ultrio
Biologics license application is submitted to FDA for a blood screening assay to detect HIV-1, hepatitis C & B in donated blood, plasma, organs and tissue. The test is intended to be marketed by Chiron and run on fully automated, high-throughput Procleix Tigris and semi-automated Procleix systems (1"The Gray Sheet" Jan. 5, 2004, p. 5)...
Lehman Brothers Global Healthcare Conference In Brief
Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...